Received 91 Karmas

[TimAlerts] For those hating on $ARWR, just a few items. First, they have a really solid RNAi platform. Had a setback recently on a trial failure which turned the chart into "bad sushi" but make no mistake as they already have a license deal with Amgen for two cardiovascular targets. They got (I think) $50 million upfront on that deal and can earn up to an additional $650 million in milestones plus royalties. That is just partner deal but they can have more. I think their business model is much like $I
Received 0 Karma
Received 1 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma
Received 0 Karma



great lesson. thanks.
Thanks Tim!
I will focus on key patterns.
Watching And Analyzing!
Join now or log in to leave a comment